KASMEJ

Kastamonu Medical Journal regularly publishes internationally qualified issues in the field of Medicine in the light of up-to-date information.

EndNote Style
Index
Original Article
Candida spp. infection frequency and risk factors in malignant critical care patients
Aims: Candida spp. can cause fatal infections in the person in case of immunosuppression such as malignancy. The aim of our study is to examine the frequency, prognosis and risk factors of candida-related infections in our patients with malignancies followed in our intensive care unit (ICU).
Methods: ICU patients with malignancy with fungal infection accepted as the case group and the patients without candida were considered as the control. Demographic characteristics, risk factors and candida risk scores were recorded and compared in both groups.
Results: Candida spp. reproduction was observed at a very high rate with 24%. However, there was no difference in mortality between the two groups with and without candida infection. In our study; candida risk score, presence and duration of central venous catheter, antibiotic and steroid use in the last 1 month were found to be the factors determining the risk of candida infection.
Conclusion: The contribution of the presence of fungal infection to mortality in our cancer patients does not seem different from others. However, in this patient group, it is difficult to distinguish colonization from invasive fungal infections. At this stage, the use of treatment decisions using risk factors and risk scoring comes to the fore.


1. Lortholary O, Renaudat C, Sitbon K, et al. Worrisome trends in incidenceand mortality of candidemia in intensive care Units. Intensive Care Med.2014;40:1303-12.
2. Magill SS, Edwards JR, Bamberg W, et al. Multistate point- prevalence survey of health care-associated infections. N Engl J Med. 2014;370(13):1198–1208.
3. Ortholary O, Renaudat C, Sitbon K, et al. The risk and clinical outcomeof candidemia depending on underlying malignancy. Intensive Care Med.2017;43(5):652-62.
4. Kullberg BJ, Arendrup MC. Invasive candidiasis. N Engl J Med. 2016;374(8):794–795.
5. Zirkel J, Klinker H, Kuhn A, et al. Epidemiology of candida blood stream infections in patients with hematological malignancies or solid tumors. Medical Myco. 2012;50(1):50–55.
6. Cornely OA, Gachot B, Akan H, et al. Epidemiology and outcome of fungemia in a cancer cohort of the Infectious Diseases Group (IDG) of the European Organization for Research and Treatment of Cancer (EORTC 65031). Clin Infect Dis. 2015;61(3):324–331.
7. Cho SY, Lee DG, Choi JK, et al. Cost-benefit analysis of posaconazole versus fluconazole or itraconazole as a primary antifungal prophylaxis in high-risk hematologic patients: a propensity score-matched analysis. Clin Ther. 2015;37(9):2019–2027.
8. Kullberg BJ, Arendrup MC. Invasive candidiasis. N Engl J Med. 2015;373(15):1445–1456.
9. Enoch DA, Yang H, Aliyu SH, Micallef C. The changing epidemiology of invasive fungal infections. Methods Mol Biol. 2017;1508:17–65.
10. Zhang Z, Zhu R, Luan Z, Ma X. Risk of invasive candidiasis with prolonged duration of ICU stay: a systematic review and meta-analysis. BMJ Open. 2020;10(7):e036452.
11. Li D, Xia R, Zhang Q. Bai C, Li Z, Zhang P. Evaluation of candidemia inepidemiology and risk factors among cancer patients in a cancer centerof china: an 8-year case-control study. BMC Infect Dis. 2017;17:536.
12. Candan M, Bakır G, Sırmatel Ö, Akkoçlu G, Çağlayan S, Sırmatel F. Kanserli hastalarda kandideminin risk faktörleri. Türk Mikrobiyol Cem Derg. 2003;33(2):143-147.
13. Bilgili B. Candida infections in intensive care unit patients: how todiagnose? Klimik Derg. 2019; 32(Suppl. 2):135-9.
Volume 3, Issue 1, 2023
Page : 22-26
_Footer